Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The price of Cytosorbents Corp (NASDAQ: CTSO) closed at $0.64 in the last session, down -0.47% from day before closing price of $0.64. In other words, the price has decreased by -$0.47 from its previous closing price. On the day, 0.3 million shares were traded. CTSO stock price reached its highest trading level at $0.68 during the session, while it also had its lowest trading level at $0.616.
Ratios:
We take a closer look at CTSO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.71 and its Current Ratio is at 2.11. In the meantime, Its Debt-to-Equity ratio is 3.04 whereas as Long-Term Debt/Eq ratio is at 2.95.
Upgrades & Downgrades
. In the most recent recommendation for this company, B. Riley Securities on September 07, 2023, initiated with a Buy rating and assigned the stock a target price of $4.
On September 17, 2020, Jefferies started tracking the stock assigning a Buy rating and target price of $15.Jefferies initiated its Buy rating on September 17, 2020, with a $15 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 19 ’25 when MARIANI PETER J bought 10,548 shares for $1.09 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTSO now has a Market Capitalization of 40144508 and an Enterprise Value of 59744512. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.17 while its Price-to-Book (P/B) ratio in mrq is 4.45. Its current Enterprise Value per Revenue stands at 1.616 whereas that against EBITDA is -4.703.
Stock Price History:
The Beta on a monthly basis for CTSO is 1.31, which has changed by -0.3021739 over the last 52 weeks, in comparison to a change of 0.17511821 over the same period for the S&P500. Over the past 52 weeks, CTSO has reached a high of $1.61, while it has fallen to a 52-week low of $0.60. The 50-Day Moving Average of the stock is -11.77%, while the 200-Day Moving Average is calculated to be -30.87%.
Shares Statistics:
According to the various share statistics, CTSO traded on average about 111.77K shares per day over the past 3-months and 137520 shares per day over the past 10 days. A total of 62.79M shares are outstanding, with a floating share count of 52.37M. Insiders hold about 16.62% of the company’s shares, while institutions hold 26.05% stake in the company. Shares short for CTSO as of 1765756800 were 1995957 with a Short Ratio of 17.86, compared to 1763078400 on 1952028. Therefore, it implies a Short% of Shares Outstanding of 1995957 and a Short% of Float of 3.45.
Earnings Estimates
The stock of Cytosorbents Corp (CTSO) is currently being evaluated by 3.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.03 and low estimates of -$0.05. Analysts are recommending an EPS of between -$0.1 and -$0.22 for the fiscal current year, implying an average EPS of -$0.17. EPS for the following year is -$0.14, with 3.0 analysts recommending between -$0.09 and -$0.19.
Revenue Estimates
According to 3 analysts, . The current quarter’s revenue is expected to be $9.85M. It ranges from a high estimate of $10.33M to a low estimate of $9.23M. As of . The current estimate, Cytosorbents Corp’s year-ago sales were $10.1MFor the next quarter, 3 analysts are estimating revenue of $9.69M. There is a high estimate of $9.69M for the next quarter, whereas the lowest estimate is $9.69M.
A total of 3 analysts have provided revenue estimates for CTSO’s current fiscal year. The highest revenue estimate was $38.16M, while the lowest revenue estimate was $37.06M, resulting in an average revenue estimate of $37.67M. In the same quarter a year ago, actual revenue was $39.2MBased on 3 analysts’ estimates, the company’s revenue will be $40.99M in the next fiscal year. The high estimate is $41.8M and the low estimate is $40.38M.
